| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790108 | Urologic Oncology: Seminars and Original Investigations | 2018 | 9 Pages |
Abstract
Our large contemporary study found an increased adoption of RARC between 2010 and 2013, with more than 1 out of 4 patients undergoing RARC by the end of the study period. We found that RARC was associated with higher LN counts, shorter LOS, and lower POM. Our results allude to potential benefits of RARC while we wait for more definitive answers from randomized trials.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Nawar M.D., Jeffrey J. M.B.B.S., M.P.H., Maxine M.P.H., David F. M.D., Thomas M.D., Firas M.D., Stuart R. Sc.D., Mani M.D., Adam S. M.D., Joaquim M.D., Toni K. M.D., Quoc-Dien M.D.,